Orion Portfolio Solutions LLC Increases Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Orion Portfolio Solutions LLC boosted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 17.2% in the 3rd quarter, Holdings Channel reports. The fund owned 10,291 shares of the medical equipment provider’s stock after buying an additional 1,508 shares during the period. Orion Portfolio Solutions LLC’s holdings in Lantheus were worth $1,129,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Signaturefd LLC raised its position in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 92 shares in the last quarter. UMB Bank n.a. raised its position in Lantheus by 42.1% during the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Lantheus by 45.5% in the third quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider’s stock valued at $51,000 after buying an additional 146 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Lantheus by 4.5% in the second quarter. Nisa Investment Advisors LLC now owns 6,643 shares of the medical equipment provider’s stock valued at $533,000 after buying an additional 287 shares in the last quarter. Finally, CWM LLC increased its position in shares of Lantheus by 63.0% in the third quarter. CWM LLC now owns 750 shares of the medical equipment provider’s stock valued at $82,000 after buying an additional 290 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on LNTH shares. Redburn Atlantic started coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price objective for the company. Truist Financial restated a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, JMP Securities cut their price objective on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Lantheus has an average rating of “Moderate Buy” and an average target price of $130.00.

Lantheus Price Performance

Shares of NASDAQ:LNTH opened at $93.02 on Friday. The business’s 50 day moving average price is $97.88 and its 200-day moving average price is $97.98. The firm has a market capitalization of $6.47 billion, a PE ratio of 15.48 and a beta of 0.45. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.